Selegiline for Parkinson's disease.
Monoamine oxidase inhibitors that have been available in the United States are nonselective and thus act equally on peripheral and brain monoamine oxidase. Recently, selegiline, a selective monoamine oxidase inhibitor, has been approved for use in the management of Parkinson's disease. Clinical trials demonstrate that selegiline in combination with carbidopa/levodopa is effective in relieving symptoms and prolonging remission. The dosage of carbidopa/levodopa can usually be reduced, resulting in diminished side effects. Selegiline is relatively nontoxic and appears to be a valuable addition in the management of Parkinson's disease.
Calesnick
B
B
Hahnemann University School of Medicine, Philadelphia, Pennsylvania.
D000978:Antiparkinson Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology; D010300:Parkinson Disease / Q000188:drug therapy*; D010627:Phenethylamines / Q000627:therapeutic use*; D012642:Selegiline / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*
D000978:Antiparkinson Agents; D008996:Monoamine Oxidase Inhibitors; D010627:Phenethylamines; D012642:Selegiline